Biotechnology

Deals, data buzz could help biotech shares exit Wall Street’s ‘no man’s land’

Field Trip Health raises largest financing in Canada for a psychedelics company

B.C.’s Eupraxia Pharmaceuticals sees lacklustre trading debut

Why the nascent psychedelics industry is getting investors’ attention

First TSX-only biotech IPO in 18 years set for next week as Eupraxia closes books on $41-million offering

Vancouver biotech Notch Therapeutics raises US$85-million in venture funding

TMX CEO aims to encourage small biotech companies to list in Canada

RBC taps into biotech surge, investing in new Lumira venture fund

Vancouver’s Khosrowshahi family to launch US$400-million pharma IPO, capitalizing on biotech craze

Rare milestone approaches for Canadian biotech sector as Aurinia awaits FDA OK to sell new drug

AbCellera Biologics’s billionaire boss planning hiring spree in Vancouver hometown after record-setting IPO

What Canada needs to do to build a world-class biotech sector

AbCellera closes record biotech IPO as underwriters exercise option to buy shares; total proceeds US$555.5-million

Which of these top 10 Canadian biotech stocks are undervalued?

AstraZeneca shares fall as investors react to $39-billion Alexion acquisition

AstraZeneca to buy U.S. drugmaker Alexion for $39-billion to expand in immunology

Vancouver’s AbCellera more than doubles IPO target size, headed for biggest debut on record for Canadian biotech

Cowen’s CEO sees gains in biotech, helped by easier access to cash

Booming Canadian biotech sector on track for record year after raising $1-billion in venture capital so far in 2020

Peter Thiel joins board of B.C. antibody therapy developer AbCellera in advance of expected IPO

Canada’s Pascal Biosciences partners with U.S. firm to test cannabis-based cancer therapy

Antibody therapy developer AbCellera hires banks for U.S. IPO, sources day

Sanofi snags another U.S. biotech firm with $3.7-billion Principia deal

CureVac doesn’t rule out accelerated approval for COVID-19 vaccine

Active management finds niche in post-pandemic market

Vancouver COVID-19 therapy developer AbCellera eyeing potential IPO as early as fall

The Globe’s stars and dogs for the week

July 9: ‘The government of the people, by Justin Trudeau, for the people.’ Readers take a closer look at the WE Charity contract, plus other letters to the editor

Streetwise newsletter: Best reads of the week

Biotech blind spot: How Canada’s big investors missed the boom happening right now

Top Canadian biotech investor on the firms most likely to turn COVID-19 drug trials into treatments and when a vaccine may arrive

The Globe’s stars and dogs for the week

BioNTech and Pfizer’s COVID-19 vaccine shows potential in human trial

Temasek-led investor group makes $250-million vaccine bet on Germany’s BioNTech

Hamilton biotech Fusion sets IPO price at $17 a share for Friday debut on Nasdaq